# GLP-1 injection sites: what “rotate” means

Site rotation means changing the exact injection spot. Your product’s device and instructions determine the rest of the routine.

Canonical: https://velri.co/blog/glp1-injection-site-rotation-routine-needle-averse-first-month
Publisher: Velri (https://velri.co/about)
Published: 2026-07-31
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Injection-site rotation means using a different spot for each injection. It does not necessarily mean switching to a different body region every time. The approved semaglutide and tirzepatide injection instructions distinguish the general area from the exact site. [1][2]

The rest of the routine depends on the product and device you were prescribed.

## Area and spot are different

The labels identify the abdomen, thigh and upper arm as injection areas, with product-specific instructions about who should administer an upper-arm injection. Tirzepatide's patient instructions explicitly say the same body area can be used as long as a different spot within it is selected. [1][2]

A brief record of the date and area used can make that instruction easier to follow. The written product instructions remain the reference for site selection and technique.

## Learn the device you actually have

A single-dose pen, a multidose pen and a vial with a syringe are different presentations. The tirzepatide label calls for training appropriate to the specific presentation being supplied. [2]

For someone uneasy about needles, a demonstration with that exact device can resolve practical uncertainties: what to prepare, how completion is recognized and how used equipment is disposed of. A video for another device may leave out a step that matters for yours. [1][2]

## Why a vial needs clear measurement instructions

The FDA has reported dosing errors with compounded injectable semaglutide, including confusion between milligrams, milliliters and syringe units. Different concentrations can make apparently similar instructions mean different amounts. [3]

Compounded products are not FDA approved, and their safety, effectiveness and quality are not reviewed before marketing. Their instructions should not be assumed interchangeable with those of an approved pen. [3]

Unclear measurement or device instructions are a reason to contact the dispensing pharmacy or prescribing clinician before using the product. That conversation should resolve the exact prescription, concentration and device rather than leave you to perform a conversion yourself. [3]

## Sources
[1] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[2] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[3] FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products | FDA (2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support